ImmunoPrecise Antibodies (IPA) News Today $1.90 +0.08 (+4.40%) As of 03:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IPA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025July 16 at 8:05 AM | businesswire.comImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price RequirementJuly 14 at 8:35 AM | financialpost.comFImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price RequirementJuly 14 at 8:35 AM | financialpost.comFImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price RequirementJuly 14 at 8:01 AM | businesswire.comImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors - MorningstarJuly 8, 2025 | morningstar.comMImmunoPrecise Antibodies Strengthens Board with Industry Veteran Jon LieberJuly 7, 2025 | tipranks.comImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training DataJuly 3, 2025 | businesswire.comImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® TechnologyJune 24, 2025 | businesswire.comWe're Keeping An Eye On ImmunoPrecise Antibodies' (NASDAQ:IPA) Cash Burn RateJune 18, 2025 | finance.yahoo.comAI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation StudiesJune 12, 2025 | financialpost.comFAI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation StudiesJune 12, 2025 | businesswire.comImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine DiscoveryJune 5, 2025 | businesswire.comImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement EffortsMay 21, 2025 | businesswire.comImmunoPrecise Antibodies (IPA) to Present at Maxim Group’s 2025 Virtual Tech ConferenceMay 20, 2025 | uk.finance.yahoo.comImmunoPrecise Antibodies to Present at Maxim Group’s 2025 Virtual Tech ConferenceMay 20, 2025 | tipranks.comImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech ConferenceMay 20, 2025 | businesswire.comIPA’s LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater SpeedMay 12, 2025 | finance.yahoo.comIPA's LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater SpeedMay 12, 2025 | businesswire.comCarterra Announces its 2025 Symposia Series on Speeding Drug Discovery with AI/ML and Other New TechnologiesApril 24, 2025 | finance.yahoo.comImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing MethodsApril 11, 2025 | uk.finance.yahoo.comImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA’s Shift to Non-Animal Testing MethodsApril 11, 2025 | financialpost.comFImmunoPrecise Antibodies Partners with RIBOPRO to Enhance Antibody DiscoveryApril 10, 2025 | tipranks.comImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q3 2025 Earnings Call TranscriptApril 1, 2025 | msn.comImmunoPrecise Antibodies reports Q3 EPS (C$0.66) vs. (C$0.10) last yearMarch 29, 2025 | markets.businessinsider.comIMMUNOPRECISE ANTIBODIES Earnings Preview: Recent $IPA Insider Trading, Hedge Fund Activity, and MoreMarch 28, 2025 | nasdaq.comImmunoPrecise Antibodies Ltd. (IPA) Q3 2025 Earnings Call TranscriptMarch 28, 2025 | seekingalpha.comImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025March 28, 2025 | businesswire.comImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.March 13, 2025 | financialpost.comFImmunoPrecise Antibodies Reschedules Q3 Financial Results ReleaseMarch 11, 2025 | tipranks.comIPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025March 11, 2025 | financialpost.comFIPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025March 11, 2025 | businesswire.comIPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025March 5, 2025 | financialpost.comFIPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025March 5, 2025 | businesswire.comImmunoPrecise Antibodies Ltd. (IPA) Expands AI Leadership with Dr. Kamil Isaev AppointmentFebruary 27, 2025 | insidermonkey.comImmunoPrecise Antibodies announces strategic collaboration with RiboproFebruary 26, 2025 | markets.businessinsider.comImmunoPrecise Antibodies and RIBOPRO Partner to Revolutionize Antibody DiscoveryFebruary 26, 2025 | tipranks.comIPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in ImmunotherapyFebruary 26, 2025 | businesswire.comImmunoPrecise Antibodies Transfers to Nasdaq Capital Market, Gains ExtensionFebruary 20, 2025 | tipranks.comImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance PeriodFebruary 20, 2025 | businesswire.comImmunoPrecise Antibodies Boosts Financial Position Through Successful Capital InitiativesFebruary 3, 2025 | tipranks.comTop 10 AI Stocks Dominating Wall StreetJanuary 27, 2025 | msn.comImmunoPrecise Antibodies Ltd. (IPA) Unveils AI-Developed GLP-1 Therapies for Type 2 Diabetes and Obesity, Pioneering New Frontiers in Biotech InnovationJanuary 27, 2025 | msn.comImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville DebentureJanuary 27, 2025 | businesswire.comThis Biotech Soared On Wednesday Following AI-Related AnnouncementJanuary 22, 2025 | msn.comIPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes TreatmentJanuary 22, 2025 | businesswire.comImmunoPrecise Antibodies Ltd. (IPA) Launches AI-Powered Drug Discovery Pipeline, Revolutionizing Therapeutic Development with LENSai™ PlatformJanuary 20, 2025 | insidermonkey.comImmunoPrecise Antibodies Launches AI-Powered Drug Discovery PlatformJanuary 17, 2025 | tipranks.comImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles InnovationJanuary 17, 2025 | financialpost.comFImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles InnovationJanuary 17, 2025 | financialpost.comFImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles InnovationJanuary 17, 2025 | businesswire.com Get ImmunoPrecise Antibodies News Delivered to You Automatically Sign up to receive the latest news and ratings for IPA and its competitors with MarketBeat's FREE daily newsletter. Email Address IPA Media Mentions By Week IPA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IPA News Sentiment▼0.760.97▲Average Medical News Sentiment IPA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IPA Articles This Week▼51▲IPA Articles Average Week Get ImmunoPrecise Antibodies News Delivered to You Automatically Sign up to receive the latest news and ratings for IPA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Arcturus Therapeutics News Benitec Biopharma News Gossamer Bio News COMPASS Pathways News Prothena News Altimmune News Aura Biosciences News Cartesian Therapeutics News Capricor Therapeutics News Amarin News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IPA) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoPrecise Antibodies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunoPrecise Antibodies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
